Can I stop taking lorlatinib once I take it?

Lorlatinib is a targeted therapy drug mainly used to treat patients with ALK-positive or ROS1-positive metastatic non-small cell lung cancer (NSCLC). As a third-generation ALK inhibitor, lorlatinib may cause some side effects while effectively inhibiting the growth of cancer cells. Therefore, the question of whether a patient can stop taking medication needs to be decided based on the individual situation and the doctor's advice.

Factors that determine whether medication can be discontinued

1.Therapeutic effect: For patients with ALK-positive or ROS1-positive non-small cell lung cancer, if the patient’s tumor is controlled after taking lorlatinib without serious side effects, it is usually not recommended to stop the drug at will. The continued use of targeted drugs can help inhibit the recurrence and metastasis of cancer cells. Therefore, patients should continue to take it under the guidance of a doctor to ensure maximum treatment effect.

2.Resistance issue: Once resistance to lorlatinib occurs, doctors may adjust the treatment plan according to the patient's specific situation. Resistance may manifest as a decrease in the drug's inhibitory effect on tumors, or an acceleration of cancer progression. In this case, the patient should not stop taking the drug on his own, but should report it to the doctor in time and choose other treatment options according to the doctor's advice, such as changing drugs or combination therapy.

3.Side Effect Management: Lorlatinib may cause some side effects, such as weight gain, hyperglycemia, depression, etc. If side effects are severe, patients should discuss with their doctor whether the dose needs to be adjusted or the drug temporarily discontinued. Doctors may decide whether to stop the medication or change the treatment plan based on the nature and severity of the side effects, but do not recommend that patients stop taking the medication on their own.

4.Individualized treatment: Each patient’s condition, drug response and drug resistance are different, so the decision to discontinue medication should be made by the doctor based on the patient’s specific condition. Patients should not stop taking the medicine without authorization to avoid affecting the treatment effect or causing tumor recurrence.

In general, lorlatinib is not a drug that patients can discontinue at will. Patients should undergo treatment under the guidance of a doctor, conduct regular reviews, and adjust the medication regimen to ensure the sustainability of the treatment effect. If you have any side effects or discomfort, you should communicate with your doctor promptly so that appropriate adjustments can be made.

xa0

Reference materials

1.UpToDate - https://www.uptodate.com/

2.China National Medical Products Administration - https://www.nmpa.gov.cn/